RAD51 and ovarian cancer: (33) evaluated, using patient-derived ovarian cancer xenografts, the baseline expression levels of RAD51 foci and demonstrated how the percentage of RAD51 positive cells correlates inversely with the response to Olaparib and directly with the risk of recurrence and platinum resistance.